NCT00001145View on ClinicalTrials.gov

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

October 31, 1999

Study Completion Date

October 31, 2003

Conditions

Immunoproliferative Disorder

Interventions

DRUG

Bacteriophage

DRUG

rhuCD40L

DRUG

KLH

Trial Locations (1)

20892

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH